title: Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value.
abstract: OBJECTIVE
  In this study we compared neutrophil-to-lymphocyte ratio (NLR) and neutrophilto- monocyte ratio(NMR) between patients with prostate cancer after first transrectal ultrasound (TRUS)- guided biopsy and patients with benign prostate hyperplasia(BPH) after second TRUS-guided biyopsy.
  
  
  METHODS
  A total of 224 patients who underwent multi (≥12)-core TRUS -guided biopsy at our clinic for elevated PSA or abnormal digital rectal examination in between January 2008 and March 2015 were retrospectively analyzed. There were 2 groups. Group 1 consisted of 146 patients with a diagnosis of prostate cancer after the first TRUSguided biyopsy and group 2 consisted of 78 patients with a diagnosis of benign prostate hyperplasia after second TRUS-guided biyopsy. Age, PSA, NLR and NMR values were compared between the two groups.
  
  
  RESULTS
  There were no statistically significant correlation between PSA and NLR(p=0.46). The mean of age, PSA, NLR, NMR values in the group 1 and 2 were respectively 64.6±7.7 and 61.6±6.9, 6.5±1.9 and 5.3±1.2, 2.8±1.5 and 2.3±1.1, 9.2±3.9, 8.1±2.9 (p=0.03, p=0.001, p=0.012 and p=0.30). The mean PSA, NLR ,NMR values of the group 1 were significantly higher than those in group 2 (p=0.002). Gleason grade and pathological stage were significantly increases as NLR increases.
  
  
  CONCLUSIONS
  NLR and NMR in patients with BPH after second TRUS-guided biopsy were lower than that of those with a diagnosis of prostate cancer after the first TRUS-guided biopsy.White blood test subtypes can be considered for the decision to perform a second TRUSguided biopsy in patients with previous negative biopsy with persistently elevated PSA.
authors.affiliation: Department of Urology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Yasin
authors.initials: Y
authors.lastname: Ceylan
authors.affiliation: Department of Urology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Bülent
authors.initials: B
authors.lastname: Günlüsoy
authors.affiliation: Department of Urology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Tansu
authors.initials: T
authors.lastname: Degirmenci
authors.forename: Deniz
authors.initials: D
authors.lastname: Bolat
authors.affiliation: Department of Urology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Zafer
authors.initials: Z
authors.lastname: Kozacioglu
authors.affiliation: Department of Pathology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Enver
authors.initials: E
authors.lastname: Vardar
authors.affiliation: Department of Urology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Yusuf Kadir
authors.initials: YK
authors.lastname: Topçu
authors.affiliation: Department of Urology. Bozyaka Research and Education Hospital. Izmir. Turkey.
authors.forename: Salih
authors.initials: S
authors.lastname: Polat
mesh_terms: D001706:Biopsy / Q000379:methods; D000066491:Clinical Decision-Making; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D009000:Monocytes; D009504:Neutrophils; D017430:Prostate-Specific Antigen / Q000097:blood*; D011469:Prostatic Diseases / Q000097:blood* / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology*; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen